McKesson reports $403.4 billion revenue and launches $2.25 billion share‑repurchase program
McKesson Corp. posted fiscal 2026 consolidated revenue of $403.4 billion, a 12% increase year over year. Earnings per diluted share rose to $38.38, while adjusted earnings per diluted share reached $39.11, an 18% gain. The company generated $3.4 billion of cash flow from operations in the fourth quarter and about $3.2 billion of free cash flow after $185 million of capital expenditures. McKesson announced a $2.25 billion accelerated share‑repurchase program and the board raised total buyback authorization to $7.7 billion. Growth was driven by higher prescription volumes in its North American pharmaceutical segment and continued expansion in oncology and multispecialty services.
Entities: Affera Pulsed Field Ablation system · Amundi · Cerity Partners LLC · Dividend Kings · First Eagle Investment Management LLC · Intuitive Surgical, Inc. · JAT Capital Management LP · Madison Asset Management LLC · McKesson Corporation · Medtronic PLC · Meta Platforms, Inc. · MiniMed
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Fiscal 2026 revenue rose 8.4% to $36.4 billion, the strongest top‑line growth in ten years. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] Medtronic raised its dividend for the 49th consecutive year in June. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] The company's share price is about $87, with a forward earnings multiple of 15 times and a forward dividend yield of 3.4%. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] Medtronic's stock has declined 33% over the past five years. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] Medtronic is launching new products including the Affera pulsed‑field ablation system, the Symplicity Spyral hypertension device and the Hugo robotic‑assisted surgery platform, and adding AI features. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] Free cash flow increased 4.6% to $5.43 billion in fiscal 2026. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] Analysts have a median price target of $100 for Medtronic and have not issued any sell rating. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] Including reinvested dividends, Medtronic delivered a negative total return of 22% over the same period. (86c9579e-3b08-466c-bd6d-d709a2dbfd37)
- [○ 1 SOURCE] McKesson launched a $2.25 billion accelerated share‑repurchase program. (McKesson fiscal 2026 report)
- [○ 1 SOURCE] McKesson's earnings per diluted share for fiscal 2026 were $38.38. (McKesson fiscal 2026 report)
- [○ 1 SOURCE] McKesson generated $3.4 billion of cash flow from operations in the quarter and $3.2 billion of free cash flow after capital expenditures. (McKesson fiscal 2026 earnings release)
- [○ 1 SOURCE] McKesson reported consolidated revenue of $403.4 billion for fiscal 2026, up 12% year over year. (McKesson fiscal 2026 earnings release)